In our study, we indeed demonstrated rosuvastatin synergized with regorafenib in blocking MEK-ERK signaling, therefore synergistic inhibiting colorectal cancer growth in vitro and in vivo. The gene discussed is MAP2K7; the disease is colorectal cancer.